

## Special Issue

# The Elderly Multiple Myeloma Patient in the Era of Quad Therapy and CAR-T Cells

### Message from the Guest Editors

Multiple-myeloma therapy continues to evolve at a breakneck pace. Yearly, we are blessed with practice-changing clinical trials that change the treatment paradigm. As CAR-T and quadruplet therapies continue to gain new label indications, patient selection will become more important in clinical myeloma care. Despite the great outcomes with these agents, the medically frail patient remains challenging to treat. Indeed, while the landmark IMROZ trial included the “transplant-ineligible,” medically frail patients as well as patients > 80 years of age were excluded. While ide-cel, in general, has a more gentle side effect profile than cilta-cel, clinicians may be dissuaded from offering a CAR-T to an elderly patient and instead opt for a bispecific t-cell engager. Here, we invite you to share your expert opinion on the care of elderly and medically frail patients in the era of quadruplet induction and CAR-T cell therapy. By doing so, we hope to help inform clinical decision making that maximizes the therapeutic index of these interventions, helping to maintain a rigorous quality of life in these patients.

---

### Guest Editors

Dr. James J. Ignatz-Hoover

Adult Hematologic Malignancies & Stem Cell Transplant Section,  
Seidman Cancer Center, University Hospitals Cleveland Medical  
Center, Cleveland, OH, USA

Prof. Dr. Koen Van Besien

UH Cleveland Medical Center, Euclid Ave, Cleveland, OH, USA

---

### Deadline for manuscript submissions

15 August 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/227140](https://mdpi.com/si/227140)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)